Publications 2006

1.

Atthobari J, Brantsma A, Gansevoort RT, Visser S, Asselbergs F, van Gilst W, de Jong PE, de Jong-van den Berg LTW. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both randomized clinical trial and an observational cohort study.
Nephrology Dialiysis Transplantation 2006;may 23:1-9.

2.

Atthobari J, Asselbergs F, Boersma C, de Vries R, Hillege H, van Gilst W, Gansevoort RT, de Jong PE, de Jong-van den Berg LTW, Postma MJ. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmavoeconomic analysis linked to the Prevention of REnal and Vascular ENdstage Disease (PREVEND) study and the prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND IT). Clinical Therapeutics 2006;28(3):432-44.

3.

Bakker M, Jentink J, Vroom F, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG An International Journal of Obstetrics and Gynaecology 2006;113:559-68.

4.

Boersma C, Atthobari J, Gansevoort RT, de Jong-van den Berg LTW, de Jong PE, de Zeeuw D, Annemans L, Postma MJ. Pharmacoeconomics of angiotensin II antagonists in Type 2 diabetic patients with Nephropathy. Pharmacoeconomics 2006;24(6):523-35.

5.

Boersma C, Radeva J, Koopmanschap M, Voors A, Postma MJ. Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to the Netherlands. Journal of Medical Economics 2006;9:121-31.

6.

Bos J, Rümke H, Welte R, Spanjaard L, van Alphen L, Postma MJ. Combination vaccine against invasive meningococcal B and pneumococcal infections. Pharmacoeconomics 2006;24(2):141-53.

7.

Bos JM, Postma MJ. The authors' reply. (Discounting health effects in pharmacoeconomic evaluations: current controversies. Birks, S. Pharmacoeconomics 2006;24(12)1273-4 ). Pharmacoeconomics 2006;24(12):1275-6.

8.

Faber A, Kalverdijk L, de Jong-van den Berg LTW, Hugtenburg J, Minderaa RB, Tobi H. Parents report on stimulant-treated children in the Netherlands: Initiation of treatment and follow-up care. Journal of Child and Adolescent Psychopharmacology 2006;16(4):432-40.

9.

Jansman FGA, Postma MJ. Costs of chemotherapy in the treatment of colorectal cancer. European Journal of Health Economics 2006;2(7):145-6.

10.

de Jong-van den Berg LTW, Faber A, van den Berg PB. HRT use in 2001 and 2004 in the Netherlands - A world of difference. Maturitas 2006;54:193-7.

11.

de Jong-van den Berg LTW. Letter to the Editors. Reply: Trends and predictors of folic acid awareness Am J Obstet Gynecol 2005;192:121-8. American Journal of Obstetrics and Gynecology 2006;194(6):1741-(letter).

12.

Kho Y, Jansman F, Prins N, Neef C, Brouwers JRBJ. Population pharmacokinetics of Oxaliplatin ( 85 mg/m2 ) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Therapeutic Drug Monitoring 2006;28:206-11.

13.

Klok RM, Boersma C, Oosterhuis I, Visser S, de Jong-van den Berg LTW. Switch patterns before and after patent expiry of omeprazole: a case study in the Netherlands. Alimentary Pharmacology & Therapeutics 2006;23:1595-600.

14.

Krapels I, Zielhuis G, Vroom F, de Jong-van den Berg LTW, Kuijpers-Jagtman A-M, Mink van der Molen A, Steegers-Theunissen R.
Periconceptional health and lifestyle factors of both affect the risk of live-born children with orofacial clefts. Birth Defects Research 2006;76(part A):613-20.

15.

Lub R, Denig P, van den Berg PB, Hoogenberg K, de Jong-van den Berg LTW. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus. British Journal of Clinical Pharmacology 2006;62(6):660-5.

16.

Meijer WM, de Jong-van den Berg LTW, van den Berg M, Verheij J, de Walle HEK. Clomiphene and Hypospadias on a detailed level: signal or change? Birth Defects Research 2006;76(a):249-52.

17.

Meijer WM, Cornel MC, Dolk H, de Walle HEK, Armstrong N, de Jong-van den Berg LTW. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descroptive study. Pharmacoepidemiology and Drug Safety 2006;15:675-82.

18.

Meijer WM, Werler MM, Louik C, Hernandez-Diaz S, de Jong-van den Berg LTW, Mitchell AA. Can folic acid protect against congenital heart defects in Down Syndrome? Birth Defects Research (part A) 2006;Clinical and molecular Teratology 76:714-7.

19.

Morré SA, Spaargaren J, Veldhuijzen I, Postma MJ, van Bergen JEAM. Evaluation of the leukocyte esterase test (LET) as pre-sreening test to reduce costs for national population-based Chlamydia trachomatis screening programs. Journal of Adolescent Health 2006;38(letter):332-5.

20.

Naunton M, Duyvendak M, Peterson GM, Brouwers JRBJ. Practice patterns in osteoporosis prevention in patients on glucocorticoids.
Osteoporos Int 2006;17(letter):634-5.

21.

Naunton M, al Hadithy AFY, Brouwers JRBJ, Archer D. Estradiol gel: review of the pharmaogology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause 2006;13(3):517-27.

22.

Postma MJ, Baltussen RMPM, Palache MA, Wilschut J. Further evidence for favorable cost-effectiveness of elderly influenza vaccination.
Expert Rev Pharmacoeconomics Outcomes Res 2006;6(2):215-27.

23.

Schirm E, de Vries T, Tobi H, van den Berg PB, de Jong-van den Berg LTW. Prescribed doses of inhaled steroids in Dutch children: too little or too much, for too short a time. British Journal of Clinical Pharmacology 2006;62(4):383-90.

24.

Smink BE, Mathijssen MPM, Lusthof KJ, de Gier JJ, Egberts ACG, Uges DRA. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine-like substances using immunoassay and LC-MS9-MS). Journal of Analytical Toxicology 2006;30:478-85.

25.

Tolley K., Postma MJ. Pharmacoeconomics and market access in Europe: case studies in Scotland and the Netherlands.
ISPOR Connections 2006;12(5):3-6.

26.

Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg LTW, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62(10):863-70.

27.

Vonkeman H, Brouwers JRBJ, van de Laar MAFJ. Understanding the NSAID related risk of vascular events. BMJ 2006;332:895-8.

28.

de Vries R, van Bergen JEAM, de Jong-van den Berg LTW, Postma MJ. Systematic screening for chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. Value in Health 2006;9(1):1-11.

29.

de Vries T, Tobi H, Schirm E, van den Berg PB, Duiverman E, de Jong-van den Berg LTW.
The gap between evidence-based medicine and daily practice in the management of paediatric asthma. A pharmacy-based population study from the Netherlands. Eur J Clin Pharmacol 2006;62:51-5.

30.

de Vries T, de Langen-Wouterse J, van Puijenbroek EP, Duiverman E, de Jong-van den Berg LTW. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol 2006;62:343-6.

31.

Vroom F, de Walle HEK, van de Laar MAFJ, Brouwers JRBJ, de Jong-van den Berg LTW. Disease-modifying antirheumatic drugs in pregnancy. Drug Safety 2006;29(10):845-63.

32.

Zito JM, Tobi H, de Jong-van den Berg LTW, Fegert JM, Safer DJ, Janhsen K, Hansen DG, Gardner JF, Glaeske G. Antidepressant prevalence for youths: a Multi-national comparison. Pharmacoepidemiology and Drug Safety 2006;15:793-8.

1.

de Jong-van den Berg LTW. SSRI's en de kans op persisterende pulmonale hypertensie bij de pasgeborene. Geneesmiddelenbulletin 2006;40(5):55-6.

2.

de Jong-van den Berg LTW, Bakker M, de Walle HEK, van den Berg PB. Duidelijk verhoogd risico op congentiale afwijkingen door het gebruik van angiotensineconverterend-enzym (ACE)-remmers in de zwangerschap.
Ned Tijdschr Geneesk 2006;150(40):2222-3.

1.

Boersma C, Postma MJ. Valsartan reduceert ziekenhuiskosten. Pharmaceutisch Weekblad 2006;4:137-9.

2.

Brouwers JRBJ, al Hadithy AFY. Geneesmiddel belicht: sarcosine. Foliolum 2006;XX(II):32.

3.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Massive venenreizungen durch periphere applikation einer hyperosmolaren lösung. Krankenhauspharmazie 2006;27(10):450.

4.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Asthmaspray zur milbenbekämfung.
Krankenhauspharmazie 2006;27(5):215.

5.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Expertenwissen als ultima ratio?
Krankenhauspharmazie 2006;27(9):405.

6.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Ineffektive therapieeinstellung durch nichtbeachtung von interaktionen. Krankenhauspharmazie 2006;27(7):312.

7.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Medikationsfehler können auch durch den patienten verursacht werden. Krankenhauspharmazie 2006;27(8):358.

8.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Fehler bei zytostatika-gabe trots (oder wegen) computerunterstütztem ärtzlichem bestellsystem. Krankenhauspharmazie 2006;27(2):70.

9.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Fehler im dosisintervall: die woche wird zum tag ...
Krankenhauspharmazie 2006;27(3):113.

10.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Ähnlich klingende Namen von wirkstoffen und fertigarzneimitteln als risiko bei der verordnung. Krankenhauspharmazie 2006;27(4):162.

11.

Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Kritische überprüfung einer sonderanforderung verhindert blutungen. Krankenhauspharmazie 2006;27(1):35.

12.

Faber A, de Jong-van den Berg LTW. Boven 50 jaar niet doorgaan met orale anticonceptiva. Interventie per brief sorteert effect.
Pharmaceutisch Weekblad 2006;41:1295.

13.

de Gier JJ. Innovatieve farmaceutische zorgconcepten. Tijdschrift voor Toekomstverkenning, strategieontwikkeling en Innovatie 2006;1:33-4.

14.

Mang B, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Mission impossible. Krankenhauspharmazie2006;27(11):510.

15.

Mang B, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Zum ersten, zum zweiten und zum dritten .... Krankenhauspharmazie 2006;27(12):541.

16.

de Vries R, Boersma C, Postma MJ. Scheve verdeling ziekenhuisopnames compliceert kostenanalyse. Valkuilen bij beoordeling kostenreductie. Pharmaceutisch Weekblad 2006;15:522-3.

1.

Brouwers JRBJ. Maag en darm ziekten. In: van Everdingen, ed. Het Medisch Handboek. Orde van Medisch specialisten ed. Utrecht/Antwerpen: Kosmos Uitgevers, 2006.

2.

Brouwers JRBJ. Gastroenterologie. In: van Everdingen & Glerum, ed. Diagnose en therapie Jaarboek.Houten: Bohn Satfleu van Loghum, 2006.

3.

de Gier J. Farmaceutische Patiëntenzorg: zorgpraktijk in perspectief. In: Hof H, van Wijck F, van der Wijst G, eds. Farma Merk Waardig.Amsterdam/Tereringen: Farma Innovatie Discussie Platform FIDP, 2006:115-20.